Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
4.110
+0.130 (3.27%)
At close: May 12, 2025, 4:00 PM
4.000
-0.110 (-2.68%)
After-hours: May 12, 2025, 7:23 PM EDT
Lantern Pharma Employees
Lantern Pharma had 24 employees as of December 31, 2024. The number of employees increased by 3 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
3
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$865,884
Market Cap
44.33M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LTRN News
- 15 hours ago - Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need - Business Wire
- 4 days ago - Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET - Business Wire
- 7 days ago - Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC) - Business Wire
- 6 weeks ago - Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results - Business Wire
- 7 weeks ago - Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - Business Wire
- 2 months ago - Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates - Business Wire
- 3 months ago - Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer - Business Wire